Tag Archives: Approved

oneM2M specifications approved by more than 190 ITU member countries as ITU standard to simplify IoT adoption

More than 190 ITU-T member countries have approved oneM2M specifications as ITU standard, simplifying the IoT ecosystem lifecycle by minimizing development, deployment, and maintenance costs. The ITU-T’s SG20 Internet of Things (IoT) and smart cities and communities (SC&C) approved oneM2M’s security specifications for IoT systems as part of the ITU-T Y.4500.3 series, making the entire… Read More »

How Aduhelm, an Unproven Alzheimer’s Drug, Got Approved

Advertisement Continue reading the main story Supported by Continue reading the main story How an Unproven Alzheimer’s Drug Got Approved Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab. The F.D.A. conducted an internal inquiry this year after allegations were… Read More »

Watchman FLX Next Gen Stroke Prevention Device Now FDA Approved

Boston Scientific’s WATCHMAN, a device that’s used to close the left atrial appendage, has done wonders for preventing the formation of clots that lead to stroke in many patients. Now the company has announced that its WATCHMAN FLX, a new and much improved version of the implant, won FDA approval. Already cleared in the European… Read More »

Brilinta Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease

Print this page June 1, 2020 — AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease. The approval by the US Food and Drug Administration (FDA) was based on… Read More »

Lynparza (olaparib) Approved in the US as a First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

Print this page 30 December 2019 — AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that Lynparza® (olaparib) has been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose… Read More »

Lasmiditan: New first-in-class drug treatment approved for migraine

Migraine is a huge medical problem, accounting for half of the disability produced by all neurologic diseases worldwide. The medication sumatriptan (Imitrex) is well known for the treatment of a migraine attack. Sumatriptan is part of a group of medications known as the triptans. Triptan medications have been in use for over 20 years and… Read More »